How should beta-blockers be chosen in patients with COPD or asthma?

• A. Use non-selective beta-blockers if possible
• B. Avoid beta-blockers entirely
• C. Use high-dose beta-blockers as first-line
• D. Use cardioselective beta-blockers if needed, but minimize use; consider nondihydropyridine calcium channel blockers if appropriate

Answer: (D)

In COPD and asthma, the airway risk from beta-blockers comes from blocking beta-2 receptors that help keep airways open. The safest approach if a beta-blocker is needed is to use a cardioselective agent—one that mainly blocks beta-1 receptors in the heart—and to keep the dose as low as possible with careful monitoring. The reason this is best is that it preserves cardiac benefits while minimizing bronchial constriction. However, even cardioselective blockers aren’t risk-free at higher doses, and selectivity can wane, so assessment of symptoms and lung function is important. If the patient has difficult-to-control airway disease or cannot tolerate beta-blockade, consider alternatives such as nondihydropyridine calcium channel blockers, which can provide rate or blood pressure control without blocking airway beta receptors. Non-selective beta-blockers should be avoided in this context because they block both beta-1 and beta-2 receptors and raise the risk of bronchospasm; using a high-dose beta-blocker increases that risk. The bottom line is to opt for cardioselective beta-blockers only when truly needed, at the lowest effective dose, with vigilant monitoring, and to turn to non-beta-blocker options when possible.